Professor Fu Xiaohui, Professor Tang Zhaohui and Professor Shi Yinghong had a big coffee conversation and talked about the BTC transformation therapy model and the future development of the Sword and Gall Heroes

*For medical professionals only

Big coffee dialogue, pointing out the future development direction of BTC, come and punch in!

In 2022, the expert interview of sofantinib "Sword and Bladder Hero Club" was officially opened, and all experts came to the scene to focus on the diagnosis and treatment and research of BTC, jointly discuss the "diagnosis and treatment secrets", and solve the puzzles for more clinicians

• TOPAZ-1 Study: The TOPAZ-1 study was a randomized, double-blind, placebo-controlled, global multicenter phase III clinical trial to evaluate the efficacy and safety of dulvalizumab combined with standardized chemotherapy alone as a first-line treatment for advanced BTC, with the primary endpoint of the study being OS

  
  

• "Triple and Four Medicines" Research: Under the leadership of Academician Fan Jia and Professor Zhou Jian, Zhongshan Hospital affiliated to Fudan University carried out a Phase II study of GEMOX chemotherapy combined with terreprimumab and lenvatinib for the first-line treatment of advanced biliary tract tumors, and the results showed that the objective remission rate (ORR) reached 80% (24/30; 95% CI: 61.

  
  

• Novel targeted drug-related translational research: sofantinib can directly inhibit tumor angiogenesis by inhibiting VEGFR1/2/3 and FGFR1, and can also reduce TAM by inhibiting CSF-1R and FGFR1, indirectly inhibiting tumor angiogenesis, thereby inhibiting tumor proliferation, and can also improve tumor immunosuppression and play a synergistic role in

  
  

Director of the Department of Surgery, Shanghai Oriental Hepatobiliary Surgery Hospital

Associate Professor and Deputy Chief Physician of the Department of Biliary Tract, Oriental Hepatobiliary Surgery Hospital

He studied under Academician Wu Mengchao, Professor Yao Xiaoping and Professor Zhang Yongjie

Visiting Scholar, University of Chicago Medical Center, USA

He is a member of the Biliary Group of the Surgical Branch of the Chinese Medical Doctor Association

Member of the Minimally Invasive Group of the Surgical Branch of the Shanghai Medical Association

Member of the American Society of Oncology Surgery

Member of the Editorial Board of the Chinese Journal of Metastatic Oncology

Member of the Editorial Board of the World Journal of Chinese Digestion

In 2011, he won the first Shanghai Yangpu District Medical Doctor Association Outstanding Clinician Award

In 2016, he was rated as the top talent in Yangpu District, Shanghai

Chief Physician of General Surgery, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Doctor

Vice Chairman and Secretary General of the Biliary Surgeon Committee of the Surgeon Branch of the Chinese Medical Doctor Association, and Chairman of the Youth Committee

He is a member of the Splen and Portal Hypertension Group of the Surgery Branch of the Chinese Medical Association

Chairman of the Hepatobiliary Professional Committee of the Bethune Foundation for Public Welfare

ERAS Expert Committee of the National Health Commission

Member of the Expert Committee on Capacity Building and Continuing Education Surgery

Vice Chairman of the Hepatobiliary Committee of the Cross-Strait Medical Exchange Association

Member of the Liver Cancer Committee of the Chinese Anti-Cancer Association

Fellow of the American College of Surgeons (FACS)

Member of the Surgical Committee of the Chinese Branch of the International Hepatobiliary and Pancreatic Association

Chinese Journal of Gastrointestinal Surgery, Chinese Journal of Metastatic Oncology, Hepatology Chinese Edition, Shanghai Medical Journal, Chinese Journal of General Basic and Clinical Studies, Journal of Abdominal Surgery Journal of Practical Hepatology and Chinese Journal of Liver Surgery and Editorial Board Member

Gastroenterology, Cancer Let, Surgical Endoscopy, Journal of the Second Military Medical University, Journal of Zhejiang University Medical Edition Special Reviewer

Visiting Scholar

Zhongshan Hospital Affiliated to Fudan University

Deputy Director of Department of Hepatopathic Surgery, Zhongshan Hospital, Fudan University

Deputy Director of the Institute of Liver Cancer of Fudan University

Standing Committee Member of the Tumor Microenvironment Committee of the Chinese Anti-Cancer Association

He is a member of the Youth Council of the Oncology Branch of the Chinese Medical Association

Deputy Leader of the Early Treatment and Early Treatment of Tumors of the Oncology Branch of the Chinese Medical Association

Vice Chairman of the Youth Council of Shanghai Anti-Cancer Association

Member of the Liver Cancer Expert Committee of the Cross-Strait Medical Exchange Association

Vice Chairman of the Youth Committee of the Liver Cancer Expert Committee of the Association of Maritime Medical Associations

Member of the Standing Committee and Deputy Director General of the Organ Transplantation Branch of the Association of Maritime Medical Associations

He is a member of the Transplant Immunology Professional Committee of the Organ Transplant Physicians Branch of the Chinese Medical Doctor Association

Young member of the Surgical Branch of the China Association for the Promotion of International Healthcare Exchanges

Deputy Secretary-General of the World Association of Chinese Physicians Oncologists

[1] Oh D Y, He A R, Qin S, et al.
A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1[J].
DOI: 10.
1200/JCO.
2022.
40.
4_suppl.
378 Journal of Clinical Oncology 40, no.
4_suppl (February 01, 2022) 378-378.
[2] Zhou J，Fan J，Shi G，et al.
Anti-PD1 antibody toripalimab，lenvatinib and gemox chemotherapy as first-line treatment of advanced and unresectable intrahepatic cholangiocarcinoma: A phase II clinical trial［J］.
Ann Oncol, 2020, 31 (suppl 4): 260-273.
This material is intended to facilitate the communication and exchange
of medical information.

This material is for the medical and health professionals only as an academic reference and is not intended for the general public and is not intended for advertising
.

For prescriptions, please refer to the drug instructions
approved by the State Drug Administration.

This material should not be distributed or forwarded
.

NP-STD-22N73-Valid Until 2024 Sep* This article is for the sole purpose of providing scientific information to medical professionals and does not represent the views of this platform